Haloperidol

From Ganfyd

rINN: Haloperidol

Other Names

Serenace^®, Haldol^®, Dozic^®

Pharmacological Information

Pharmacology Images

Haloperidol Molecule

Haloperidol in the:

BNF-registration required
BNF for children-registration required

DrugBank on Haloperidol

PubDrug on Haloperidol

UK SPCs of medicines with marketing authorisation

UK directory of medicines

UK Medicine Guide (eg pictures of capsules)

Metabolism & Interactions

CYP1A2,CYP2D6

Mechanism of Action

antipsychotic

Relevant Clinical Literature

Pubmed on Haloperidol

NHS Evidence on Haloperidol

RCT with Haloperidol   from Pubmed

Systematic reviews   from Pubmed

TRIP Database on Haloperidol

N Eng J Med, Lancet,JAMA, BMJ   from Pubmed

Cochrane Collaboration   from Pubmed

Google Scholar on Haloperidol

Other Literature

PubChem on Haloperidol

CTD (Comparative Toxicogenomics Database) link

ChemIndustry.com link

Protein Structural Information

Biological Information (GenomeNet)

Protein Knowledgebase (UniProtKB)

Please read pharmacological data limitations

Introduction

Administration

Dosage for psychiatric disorders

Indications: schizophrenia (and other psychoses), mania. Also short-term management of agitation or violent behaviour

• Initially 1.5-3mg three times a day
• Suggested that initial dose is halved in the elderly
• Max. 30mg/day (max. intramuscular dose 18mg/day)

Depot preparations

Indications: maintenace in schizophrenia (and other psychoses)

• Initially 50mg every 4 weeks (12.5-25mg in the elderly)
• Increase in 50mg increments
• Maximum dose 300mg every 4 weeks

Class Clinical Issues

Contra-indications

Dementia is probably a contraindication for any antipsychotic (fair evidence for increased mortality in long term use) and has an interesting medicolegal potential as it is unclear if following recent changes in datasheets (SPCs) and warnings from the regulatory authorities (eg FDA) any manufacturer will share liability for out of licence use (off license) use in newly commenced patients. In the UK an urgent review is taking place as of 2008.

• CNS depression
• Phaeochromocytoma

Cautions

• Driving
• Breast feeding and pregnancy (many contra-indicated or best avoided)
• Withdrawal should be gradual
• Hepatic impairment
• Renal impairment
• Cardiovascular disease
• Parkinsonism
• Epilepsy
• Blood dyscrasias
• Depression
• Myasthenia gravis
• Associated with increased venous thromboembolic disease

Side-effects

• Postural hypotension
• Parkinsonism
• Dystonia
• Akathisia
• Tardive dyskinesia
• Jaundice
• Drowsiness
• Apathy
• Excitement
• Neuroleptic malignant syndrome
• Insomia
• Anticholinergic side-effects
• Blood dyscrasias
• Hyperprolactinaemia
• Weight gain
• Skin pigmentation (purple)
• Photosensitisation at higher doses
• Cataracts & corneal opacities

Clinical Issues

Contra-indications

Cautions and Interactions

Side effects

Special advice

Pharmacology